canertinib has been researched along with sb 202190 in 3 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (sb 202190) | Trials (sb 202190) | Recent Studies (post-2010) (sb 202190) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 651 | 0 | 202 |
| Protein | Taxonomy | canertinib (IC50) | sb 202190 (IC50) |
|---|---|---|---|
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | 0.08 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 2.95 | |
| Tyrosinase | Mus musculus (house mouse) | 0.03 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.08 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.188 | |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | 0.08 | |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | 0.1038 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.0625 | |
| Tau-tubulin kinase 2 | Homo sapiens (human) | 9.34 | |
| large T antigen | Betapolyomavirus macacae | 4.87 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
3 other study(ies) available for canertinib and sb 202190
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |